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FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC 
PATIENTS TREATED WITH INHALED CORTICOSTEROIDS,  
IN REAL LIFE
Maunoury F1, VanHille JL2, Véron N2, Bounekkar A1, Fantino B3, Auray JP1, Launois R4
1Claude Bernard University Lyon 1, Villeurbanne, France, 2Regional Health Insurance Medical 
Service, Orléans, France, 3ADIM-AGORAS, Lyon, France, 4REES, Paris, France
OBJECTIVES: To estimate the cost-effectiveness impact of the French gatekeeping         
system on chronic patient treated with inhaled corticosteroids (ICS). The study ques-
tion is: Can an incentive economic system as the French gatekeeping (“coordinated 
care pathway”-CCP, August 2004 French Health Insurance reform) have a signiﬁcant 
cost-effectiveness impact, from the French Health insurance perspective. METHODS: 
A working group has been set up, in region Centre, to produce a retrospective Health 
insurance database comparative study. A total of 290 patients in each group were 
included (e.g. the totality of the non-gatekeeping group available in the database), men 
and women, from 16 to 50 years old, treated with ICS over a minima period of three 
consecutive months. The propensity score method (PS) was used in order to reduce 
selection bias from 12 covariates and a semi-Markovian decision model was per-
formed for comparing costs and effectiveness results between treated group and base-
line group, based on these matched individuals. RESULTS: According to the propensity    
score method based on 12 covariates included in the matching algorithm, a 10,000 
individuals bootstrap simulation gave an incremental cost-effectiveness ratio (ICER) 
equal to a49,084 (a48,537; a49,632) per additional patient with a well-controlled 
respiratory disease. The semi-Markovian model, based on these groups matched, 
estimates on one-year horizon a 10,000 bootstrap ICER equal to a34,640 (CI95%: 
[a34,246; a35,033]). To go further, based on the Briggs et al ﬁndings measuring the 
relationship between respiratory disease well controlled or not and QALYs, the new 
ICER ranges from 30,468 euros to 44,157 euros per QALY gained, thus included in 
the European Economic Community thresholds deﬁned by the World Health Organi-
zation (($200023,927 to $200071,781). CONCLUSIONS: This retrospective study on    
annual observational data has shown that the coordinated care pathway strategy is 
cost-effective in the management of chronic patients treated with inhaled corticoster-
oids, from the French Health insurance perspective.
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THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING 
CESSATION IN POLAND
Walczak J, Nogas G, Dybek-Karpiuk A, Augustynska J, Stelmachowski J, Garbacka M, 
Obrzut G, Pawlik D
Arcana Institute, Cracow, Poland
OBJECTIVES: The aim of the analysis was to estimate the costs and effectiveness of 
varenicline versus existing smoking cessation strategies in Poland. METHODS: A 
Markov model, the Beneﬁts of Smoking Cessation on Outcomes (BENESCO) con-
structed in MS Excel® was used in the analysis. The smoking cessation strategies were 
varenicline, bupropion, nicotine replacement therapy (NRT), unaided cessation and 
placebo. The target population consisted off adult smokers and the time horizon in 
the model was lifelong. The analysis was performed from both payers’ perspective 
(National Heath Fund and patient). The costs and beneﬁts were discounted at 5% 
and 3.5% annual rate respectively. The utilities for the included smoking related 
disease were sourced from the published literature. The quality adjusted life-years 
(QALY), life years gained (LYG), additional smoking cessation case and additional 
avoidance of chronic obstructive lung disease (COPD) were used to estimate effective-
ness of treatment strategies. A probabilistic and univariate sensitivity analysis was 
performed to estimate variability of the obtained results relative to used data. 
RESULTS: Cost of gaining one additional QALY using varenicline versus bupropion, 
NRT, unaided cessation or placebo was respectively 8,750 PLN; 6,140 PLN; 8,827 
PLN and 14,130 PLN. Cost of receiving one additional LYG using varenicline versus 
bupropion, NRT, unaided cessation or placebo was 12,360 PLN; 8,673 PLN; 12,469 
PLN and 19,961 PLN. Cost of one additional smoking cessation case using varenicline 
versus existing smoking cessation strategies was 6,260 PLN to 10,247 PLN and costs 
of one avoidance of COPD case was 27 PLN to 62 PLN. CONCLUSIONS: Results 
of the analysis indicate that varenicline is more effective and more expensive than 
alternative options for smoking cessation. Incremental cost-effectiveness ratios are 
below the acceptable threshold, therefore the varenicline can be considered as highly 
cost-effective treatment.
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CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR 
PATIENTS WITH CHRONIC RESPIRATORY DISORDER?
Maunoury F1, VanHille JL2, Véron N2, Bounekkar A1, Fantino B3, Auray JP1, Launois R4
1Claude Bernard University Lyon 1, Villeurbanne, France, 2Regional Health Insurance Medical 
Service, Orléans, France, 3ADIM-AGORAS, Lyon, France, 4REES France, Paris, France
OBJECTIVES: To estimate the cost-effectiveness impact of the French gatekeeping         
system on chronic patient treated with inhaled corticosteroids (ICS). The study ques-
tion is: Can an incentive economic system as the French gatekeeping (“coordinated 
care pathway”-CCP, August 2004 French Health Insurance reform) have a signiﬁcant 
cost-effectiveness impact, from the Health care system perspective. METHODS: A 
retrospective Health insurance database comparative study was performed. A total of 
290 patients in each group were included (e.g. the totality of the non-gatekeeping 
group available in the database), men and women, from 16 to 50 years old, treated 
with ICS over a minima period of three consecutive months. The propensity score 
method (PS) was used in order to reduce selection bias from 12 covariates and a 
semi-Markovian decision model was performed for comparing costs and effectiveness 
results between treated group and baseline group, based on these matched individuals. 
RESULTS: The semi-Markovian model, based on these groups matched, estimates on          
one-year horizon a 10,000 bootstrap incremental cost-effectiveness ratio (ICER) equal 
to a33,579 (CI95%: [a33,197; a33,960]) per QALY gained. This result is a relevant 
decisional criterion which is lower than the thresholds (1 to 3 GDP per capita) recom-
mended by the World Health Organization ($200023,927 to $200071,781 for the Euro-
pean Economic Community, region A). CONCLUSIONS: This retrospective study   
on annual observational data has shown that the French gatekeeping system is cost-
effective in the management of patients with chronic respiratory disorder, from the 
health care system perspective.
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COST-EFFECTIVENESS OF GRAZAX IN THE PAEDIATRIC POPULATION 
FOR THE TREATMENT OF GRASS POLLEN INDUCED 
RHINOCONJUNCTIVITIS IN GERMANY
Whitehead SJ1, Taylor MJ1, Bech PG2, Prenzler A3
1University of York, York, UK, 2ALK-Abelló, Hørsholm, Denmark, 3Leibniz University of 
Hannover, Hannover, Germany
OBJECTIVES: To evaluate the cost-effectiveness of a grass allergen immunotherapy 
tablet, Grazax (ALK-Abelló A/S) in combination with symptomatic medications com-
pared to the standard care of symptomatic medications alone for the treatment of 
grass pollen induced rhinoconjunctivitis. The analysis focuses on children, either with 
or without co-existing asthma, for the German setting. METHODS: The two treat-
ment options were evaluated in terms of costs and health outcomes using a decision 
tree approach. The analysis was undertaken from the payer’s perspective, with only 
direct costs included in the base case. The model followed a cohort of 1000 hypotheti-
cal children over nine years in the reference case. Continuous use of Grazax was 
modelled, with the effects of treatment captured in terms of symptom management, 
resource utilisation and allergic asthma development. Data inputs were drawn from 
published studies, databases and published clinical trials. RESULTS: The use of 
Grazax plus symptomatic medications compared to standard care showed an improve-
ment in patient outcomes; 6.92 QALYs as opposed to 6.82 QALYs over the nine-year 
time horizon. The total cost per patient treated with Grazax was a4117 compared to 
a1,502 for standard care. The resulting incremental cost per QALY is a25,900. The 
QALY gains are a result of increased quality of life related to effective symptom 
management and the reduction in allergic asthma development. Sensitivity analysis 
carried out around key parameters shows that the results estimated by the model 
remain robust. CONCLUSIONS: The analysis found Grazax treatment to have an 
incremental cost per QALY which falls below commonly accepted willingness to pay 
thresholds. Therefore, Grazax is a cost-effective option for the treatment of grass 
pollen induced rhinoconjunctivitis for children in Germany.
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MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD 
IN GERMANY
Menn P, Holle R
Institute of Health Economics & Health Care Management, Helmholtz Center Munich, 
Neuherberg, Germany
OBJECTIVES: To develop a Markov model for health-economic evaluations of COPD 
in Germany that allows estimating the cost-effectiveness of interventions, and to 
demonstrate the applicability of the model by evaluating a smoking cessation program 
compared with usual care. METHODS: A seven-stage Markov model (disease stages 
I to IV according to GOLD classiﬁcation, post-surgery, post-transplantation and 
death) was developed to conduct a cost-utility analysis from the societal perspective 
with a time horizon of 60 years. Exacerbations were subclassiﬁed into mild, moderate 
and severe. Stage-speciﬁc probabilities (for smokers and ex-smokers), utilities and 
costs were estimated based on German data where possible. Uni- and multivariate as 
well as probabilistic sensitivity analyses were conducted to assess the robustness of 
the results. A discount rate of 3% was applied to costs and effects. RESULTS: The 
smoking cessation program was the dominant strategy compared with usual care, as 
it resulted in an increase in health effects of 0.5 QALYs and a cost reduction of a1000. 
Sensitivity analyses showed that uncertainty associated with the model result was 
mostly due to the lack of evidence for costs in early disease stages. CONCLUSIONS: 
The model allows estimating the long-term cost-effectiveness of interventions for 
COPD from a societal perspective in Germany. The smoking cessation program evalu-
ated exemplarily was more effective than usual care as well as cost-saving. Although 
the majority of patients suffer from mild or moderate COPD, data on resource use in 
Germany are lacking for these early stages. These data are needed to assess the societal 
burden of the disease and the cost-effectiveness of interventions.
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ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT 
ASTHMA: A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES 
AND RELATED COST/UTILITY
Dal Negro RW1, Pradelli L2, Micheletto C1, Tognella S1, Iannazzo S2
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OBJECTIVES: Omalizumab is an innovative treatment for difﬁcult-to-treat allergic        
asthma. The mechanism of action of this type of treatment relies on impeding the 
binding of IgEs to their cellular receptor, thus blocking the inﬂammatory cascade. 
Objective of this study is to assess real-world clinical and economical outcomes associ-
ated to add-on omalizumab in difﬁcult-to-treat allergic asthmatics. METHODS: In the  
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present study, we report on the clinical and economical outcomes associated with 
omalizumab use in a cohort (n  23) of Italian adult asthmatics treated for a mean of 
10 months (range: 2–22). The pharmacoeconomic value of the treatment is assessed 
with the cost/utility ratio evaluation. RESULTS: Omalizumab signiﬁcantly improved   
asthma control and these patients’ health-related quality of life, with respect to the 
year preceding its inclusion in their therapeutic strategy. Despite reducing the costs of 
symptomatic drugs and hospital care for this patient population, the net economic 
effect of omalizumab introduction is an estimated increase of about a350 in overall 
monthly costs. However, when related to the increase in health beneﬁts, this cost 
increase results in an incremental cost/utility ratio of about a26,000/quality-adjusted 
life years gained, a favourable value according to the willingness to pay for health ben-
eﬁts in industrialised countries. CONCLUSIONS: Omalizumab therapy signiﬁcantly   
improved clinical outcomes in difﬁcult-to-treat asthmatic patients. Costs also increased, 
but this increase appears to be justiﬁed by the important clinical beneﬁts achieved.
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QUALITY OF LIFE AND WORK PRODUCTIVITY IN ALLERGIC RHINITIS 
PATIENTS SUFFERING FROM BOTH NASAL AND OCULAR 
SYMPTOMS—AN OBSERVATIONAL, CROSS SECTIONAL STUDY  
IN 4 COUNTRIES IN EUROPE
Gueron B1, Virchow JC2, Cristino J3
1GSK, Marly le Roi, France, 2Universitatsklinik Rostock, Rostock, Germany, 3Adelphi Group, 
Bollington, Cheshire, UK
OBJECTIVES: It is hypothesised that the presence of ocular manifestations (Oc         Ns) 
in addition to nasal symptoms (Ns) places an additional burden on Allergic Rhinitis 
patients. This study investigated the impact on the Quality of Life (QoL) and Burden 
of Illness (BoI) among AR patients in France, Germany, Italy and Spain. METHODS: 
The data were drawn from a cross-sectional study of consulting patients undertaken 
in May/June 2008 (Adelphi). Data were collected by doctors who included records 
relating to the next consecutive 4–5 patients consulting for AR. Patients were invited 
to ﬁll out self-completion questionnaires: QoL and work productivity measures such 
as Mini-RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire), PSQI (Pittsburgh 
Sleep Quality Index) and WPAI (Work Productivity and Activity Impairment question-
naire). Propensity scoring (PS) methods were used to match the two comparison 
groups (OcNs patients vs Ns only) RESULTS: The total sample size was 750 and       
70% of these patients (526) presented with both symptoms (OcNs). The results were 
consistent in all domains of the QoL tools with OcNs patients displaying poorer 
QoL. Clinically differences were found in the overall quality of life (RQLQ) score 
(2.54 vs. 1.96, p  0.01). Regarding sleep quality (measured by the PSQI), the global 
score showed a statistically difference (5.41 vs. 4.57, p  0.05), with the OcNs group 
falling in the “poor sleepers” category (score above 5). Regular activities (36% vs. 
29%, WPAI : AS percent impairment, P  0.05) and impact on work (0.8 vs. 0.3 days, 
time off work due to AR in the last 3 months, p  0.05) also showed a higher burden 
in OcNs patients. CONCLUSIONS: AR patients with both ocular and nasal symp-       
toms have signiﬁcantly poorer QoL and quality of sleep and take more time off 
work/usual activities than those with nasal symptoms only. These patients would 
beneﬁt from therapies that are proven to speciﬁcally address ocular symptoms in 
addition to nasal symptoms.
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IMPACT OF OCULAR SYMPTOMS ON RESOURCE UTILISATION  
AND WORK PRODUCTIVITY IN MANAGEMENT OF AR—AN 
OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES  
IN EUROPE
Gueron B1, Virchow JC2, Cristino J3
1GSK, Marly le Roi, France, 2Universitatsklinik Rostock, Rostock, Germany, 3Adelphi Group, 
Bollington, Cheshire, UK
OBJECTIVES: It is hypothesised that the presence of ocular symptoms (Oc         Ns) in 
addition to nasal symptoms (Ns) results in additional resource utilization. This study 
investigated the impact on burden of illness (BoI) among AR patients in France, 
Germany, Italy and Spain. METHODS: The data were drawn from a cross-sectional       
study of consulting patients undertaken in May/June 2008 (Adelphi). Data were col-
lected by doctors who included records relating to the next consecutive 4–5 patients 
consulting for AR. Patients were invited to ﬁll the WPAI (Work Productivity and 
Activity Impairment) questionnaire. Propensity scoring (PS) methods were used to 
match the two comparison groups (OcNs patients vs Ns only). RESULTS: A total 
of 1009 patients meeting the inclusion criteria of which 69% (700) presented with            
both symptoms (OcNs). The OcNs patients were prescribed 15% more AR medica-
tions (e.g. inhaled nasal corticosteroids, NSAs; 1.6 vs. 1.4, p  0.05) and required 
23% more consultations with health care services concerning their AR condition (4.9 
vs. 4.0, p  0.05). Of the 1009, 750 ﬁlled in the self-completion questionnaire (includ-
ing 526 OcNs patients). All work related AR WPAI domains were statistically dif-
ferent with OcNs patients recording greater impact including proportion of work 
time (hours) missed due to AR in the last 7 days (3.3% vs. 0.7%, p  0.05), impair-
ment while working (hours worked in the last 7 days, 32.6% vs. 21.8%, p  0.05) In 
addition, OcNs patients recorded more actual days off work due to AR over the 
preceding 3 months compared with patients with nasal symptoms only (0.8 vs. 0.3 
days p  0.05). CONCLUSIONS: AR patients with both ocular and nasal symptoms        
place a signiﬁcant additional burden on resource utilisation and experience greater 
lost productivity than those with nasal symptoms only. Therapies that are proven to 
speciﬁcally address ocular in addition to nasal symptoms would result in beneﬁts from 
both the direct and indirect costs associated with AR.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes Studies
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PRESCRIPTION PATTERNS OF AND TREATMENT ADHERENCE TO 
INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR 
ANTAGONISTS AMONG ASTHMATIC CHILDREN
Blais L1, Ducharme F2, Kettani FZ1
1Université de Montréal, Montreal, QC, Canada, 2Univerité de Montréal, Montréal, QC, 
Canada
OBJECTIVES: To compare prescription patterns and treatment adherence to inhaled 
corticosteroids (ICS) and leukotriene-receptor antagonists (LTRA) among asthmatic 
children. METHODS: Using the Quebec (Canada) administrative health databases, 
we identiﬁed a cohort of 27,355 asthmatic children aged 5 to 15 years in whom 
monotherapy with ICS or LTRA was initiated between January 1, 1998 and August 
31, 2005. Prescription patterns were examined by the proportion of days’ supply 
prescribed (PDSP: number of days with supply prescribed from all physicians a patient 
consulted over the number of days of follow-up). Adherence to therapy was estimated 
by the proportion of prescribed days covered (PPDC: number of days’ supply dis-
pensed over the number of days’ supply prescribed during the follow-up). The mean 
PDSP and PPDC were compared between ICS and LTRA patients using t-tests. All 
analyses were stratiﬁed by the presence or the absence of an asthma exacerbation in 
the year prior to treatment initiation with ICS or LTRA. RESULTS: Among patients 
who had an asthma exacerbation, 7427 initiated ICS and 67 initiated LTRA therapy. 
Corresponding ﬁgures were 19439 and 422 among patients who did not have an 
asthma exacerbation. The mean PPDC was similar between ICS and LTRA users in 
both strata (68.0 % vs 64.7% in the exacerbation stratum and 63.9 vs 62.7 in the no 
exacerbation stratum), but the PDSP was signiﬁcantly lower among ICS users (32.8% 
vs 55.9% (p-value 0.001) in the exacerbation stratum and 34.0% vs 51.9% (p-value 
0.001) in the no exacerbation stratum). CONCLUSIONS: Asthmatic children treated 
with ICS and LTRA had similar treatment adherence to the prescribed medications, 
but ICS appeared to be more frequently prescribed as an intermittent rather than a 
daily controller therapy, resulting in lower usage of ICS.
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ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, 
“TAILORED” METHOD OF QUITTING SMOKING
Taieb C
PFSA, Boulogne, France
INTRODUCTION: In a recent report, AFSSAPS (the French Health Products Safety 
Agency) discussed to what extent the dose selected constitutes an important success 
factor. OBJECTIVES: Assess the impact of quitting smoking in subjects receiving treat-
ment by nicotine patches, combined in some cases (and others not, depending on the 
practitioners’ approach) with nicotine pastilles to suck. METHODS: Each of the sub-
jects was included after they had expressed, during the spontaneous consultation, their 
desire to quit smoking. The cohort being pragmatic, no prescription advice was given, 
directly or indirectly, to the investigating doctors. The doctors were recruited by an 
independent service provider. Should the name of the products used not be cited? 
RESULTS: A total of 215 subjects were recruited by 67 general practitioners. Two            
analysis groups were organised, the ﬁrst group being treated with a transdermal device 
or skin patch (n  93) and the second with a transdermal device combined with pastilles 
(n  122). After 6 months, the rate of abstinence in the “Patch  Pastille” group was 
62.1% versus 39.7% in the “Patch only” group, the difference observed being signiﬁcant 
(p  0.008). CONCLUSIONS: This cohort, carried out in real conditions, highlights—in 
subjects wishing to quit smoking—the relevance of adjusting the dose with the help of 
pastilles. Therefore, it would appear that, for subjects quitting smoking, combining 
pastilles with a transdermal nicotine substitute is indispensable. The role of the health 
professional initiating the quitting programme is therefore of prime importance.
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DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT 
UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT
Petrillo J1, Mactier S2, Davies E3, Cairns JA1
1London School of Hygiene and Tropical Medicine, London, UK, 2United BioSource 
Corporation, Bethesòn, MD, USA, 3United BioSource Corporation, London, UK
OBJECTIVES: To develop and validate an algorithm to report utilities from the 
EXACT for use in cost-effectiveness studies in the UK. Current methods to derive 
utilities for exacerbations of COPD tend to be insensitive and unresponsive to change, 
including the widely used EQ-5D. There is a need to develop a measure that captures 
the full exacerbation experience with precision and responsiveness. The EXACT is a 
condition-speciﬁc PRO developed to measure the frequency, severity, and resolution 
of COPD exacerbations. METHODS: The EXACT items reduced using Rasch analy-
ses. Remaining items and levels grouped to form health states. States cognitively 
debriefed using patients to ensure combined wording and structure were appropriate. 
Members of the general public interviewed to value 11 health states each (including 
best/worst states) using the time trade-off (TTO) technique from full health/dead over 
10 years, with worse than dead values possible. Analyses include regression techniques 
to develop models that best predict utilities. Models assessed by number of inconsisten-
cies in the health state utilities, adjusted R2, and mean squared errors. Selected model 
validated using two separate datasets—one to test the predictive properties and one 
to test responsiveness and construct validity. RESULTS: Five items with 3 to 5 levels 
were selected to comprise the EXACT-U. Health states debriefed with 14 patients 
experiencing an exacerbation within the last 6 months. Total of 60 health states 
